louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03279016: Arthroscopic Guided Synovial Biopsies
Official title: Diagnosis of Temporomandibular Joint Arthritic Disease Using Arthroscopic Guided Synovial Biopsies
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Temporomandibular Arthritis
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2017-09-12
Enrollment: 20
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patient complaing from arthritis symptoms,an diagnosed as arthritic patient with MRI

Brief summary: To detect accuracy of serology in diagnosis of temporomandibular joint arthritis.

Detailed description: According to a search of previously published studies on accuracy of serology no sensitivity or specificity data was found regarding accurate detection of arthritis through serology, hence the aim of this study is to detect accuracy of serology in diagnosis of temporomandibular joint arthritis.

Eligibility criteria: Inclusion Criteria:

* Patients suffering from TEMPOROMANDIBULAR JOINT ARTHRITIS.
* Patients should be free from any systemic disease that may affect normal healing and predictable outcome.
* Patients who will agree to the consent

Exclusion Criteria:

* Patients with any systemic disease that may affect normal healing.
* Pregnant females.
* Patients with acute infection.
* Patients with bony ankyloses.
* Patients with risk of tumor dissemination.

Primary outcomes:
measure: accuracy of serology
timeFrame: 2 years
Secondary outcomes:
measure: Rheumatoid factor
timeFrame: 2 years
measure: C-reactive protein
timeFrame: 2 years
measure: Anti-Cyclic Citrullinated Peptide
timeFrame: 2 years
measure: ANA
timeFrame: 2 years
measure: HLA-B27
timeFrame: 2 years
measure: Cellular population- type
timeFrame: 2 years
measure: Cellular population- number of cells
timeFrame: 2 years
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Oral and Dental Medicine
city: Cairo
country: Egypt
facility: Faculty of Oral and Dental Medicine
Study officials:
affiliation: professor of oral and maxillofacial surgery,faculty of oral and dental medicine,Cairo university
name: sameh mekhaimer, professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT01397916: Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL)
Official title: The Activity of Indoleamine 2,3-dioxygenase in Patients With Chronic Lymphocytic Leukemia (CLL)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: CLL
Keywords: CLL
IDO
Lead sponsor: Tampere University Hospital
Sponsor class: OTHER
First posted: 2011-07-20
Enrollment: 73
Sex: ALL
Minimum age (years): 15
Maximum age (years): 85
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with CLL

Brief summary: The Activity of Indoleamine 2,3-dioxygenase in patients with Chronic Lymphocytic Leukemia (CLL) is studied.

Detailed description: The Activity of Indoleamine 2,3-dioxygenase in patients with Chronic Lymphocytic Leukemia (CLL)is studied in patients and healthly controls.

Eligibility criteria: Inclusion Criteria:

* Patients with CLL and lymphocyte count \> 10 x 109/l

Exclusion Criteria:

* Acute infection

Primary outcomes:
measure: IDO activity and expression measured by kynurenine/tryptophan ratio in serum and by PCR in peripheral blood mononuclear cells.
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Tampere
country: Finland
facility: Tampere university Hospital
Study officials:
affiliation: Tampere University Hospital
name: Marjatta Sinisalo, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03905616: HIERARCHY OF VISION
Official title: Hierarchical Processing of Visual Movement
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Neurologic Signs
Keywords: Vision
perception
BOLD activity
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2019-04-05
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Little is known about the exact role of feedback in cortical processing. Hypotheses on its function range from attentional control to the transmission of Bayesian priors in the interpretation of sensory events, such as in the theory of Predictive Coding. Recent advances in identification of functional signatures of feedback and feedforward signal, as well as additional techniques based on causal relations in signal processing open a unique methodology for probing such processes in awake and behaving organisms and testing these theories and more generally the hierarchical processing between cortical areas.

The objective of this project is to study feedback and feedforward relations and localization in the well established pathways between cortical areas V1 and Medial Temporal (MT) that have been implicated in early integration processes in motion perception.


Eligibility criteria: Inclusion Criteria:

* Aged between 18 and 40 years old
* Affiliated to a social security scheme
* Be right-handed
* Have signed the informed consent

Exclusion Criteria:

* Subjects with a neurological or psychiatric history
* Subjects with visual disturbances not corrected
* Pregnant, lactating or childbearing women without contraception.
* Persons under guardianship, trusteeship or any other administrative or judicial measure of deprivation of rights or liberty, as well as adults protected by law.
* Participants refusing to be informed of the results of the medical examination.
* Participants refusing to be informed of the possible detection of an anomaly.
* Volunteers with contraindications to the MRI examination: people using a pacemaker or an insulin pump, persons wearing a metal prosthesis or an intracerebral clip as well as claustrophobic subjects, neurosensory stimulator or implantable defibrillator, cochlear implants, ferromagnetic foreign body ocular or cerebral close to the nerve structures, agitation of the subject (non-cooperating or agitated subjects), ventriculoperitoneal neurosurgical bypass valves, dental apparatus.

Primary outcomes:
measure: Non-invasive Blood oxygenation level dependent (BOLD) fMRI activity
timeFrame: At inclusion
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02881216: Procedural Advantages of a Novel Drug-Eluting Coronary Stent
Official title: Procedural Advantages of a Novel Drug-Eluting Coronary Stent With Ultra-Thin Struts and Bioabsorbable Abluminal Polymer Coating in an All-Comers Registry
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Coronary Artery Disease
Lead sponsor: University Hospital Heidelberg
Sponsor class: OTHER
First posted: 2016-08-26
Enrollment: 814
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study sought to compare procedural performance of a new coronary stent generation, that is already available in Germany, with hitherto established current drug-eluting stents.


Eligibility criteria: Inclusion Criteria:

* CAD for PCI, consecutive patients

Exclusion Criteria:

* Age under 18
* Bare Metal Stents or Scaffolds

Primary outcomes:
measure: In-hospital major cardiac adverse events
timeFrame: One week post-procedure
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02278016: Biological Markers for the Diagnosis of Central Nervous System Infective Diseases
Official title: Diagnosis Value of Procalcitonin, Interleukin-6, AgiotensininⅡin the Cerebrospinal Fluid of Patients With Central Nervous System Infective Diseases
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Infection
Keywords: procalcitonin
interleukin-6
agiotensininⅡ
Lead sponsor: Xijing Hospital
Sponsor class: OTHER
First posted: 2014-10-29
Enrollment: 150
Sex: ALL
Minimum age (years): 13
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: More than 12 years old; meet the clinical diagnostic criteria for the central nervous system infection disease

Brief summary: Bacterial meningitis is a potentially life-threatening disease that is associated with substantial neurological morbidity and mortality. Accurate diagnosis is essential to improve outcome and prevent antibiotic overuse. Here we try to explore new biological markers for the diagnosis of the central nervous system infection disease.

Detailed description: To investigate the diagnosis value of procalcitonin,interleukin-6, agiotensininⅡin the cerebrospinal fluid in the central nervous system infection disease.

Eligibility criteria: Inclusion Criteria:

1. Aged 13 years or older;
2. At least two of the following clinical characteristics:headache, fever, neck stiffness, mental symptoms or consciousness impairment or seizures
3. Patients' family signed informed consent.

Exclusion Criteria:

1. Contraindications to lumbar puncture
2. Patients with active malignancy

Primary outcomes:
measure: Levels of procalcitonin, interleukin-6, agiotensininⅡ in the serum and cerebrospinal fluid
timeFrame: 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Xian
country: China
facility: Xijing Hospital
state: Shaanxi
Study officials:
affiliation: The Department of Neurology , Xijing Hospital
name: jiang wen, MD
role: STUDY_CHAIR
References:
citation: Li W, Sun X, Yuan F, Gao Q, Ma Y, Jiang Y, Yang X, Yang F, Ma L, Jiang W. Diagnostic Accuracy of Cerebrospinal Fluid Procalcitonin in Bacterial Meningitis Patients with Empiric Antibiotic Pretreatment. J Clin Microbiol. 2017 Apr;55(4):1193-1204. doi: 10.1128/JCM.02018-16. Epub 2017 Feb 8.
Clinical trial NCT03484416: Routine Calcium for Preventing Hypocalcemia
Official title: Routine Low-dose Calcium and Vitamin D Supplementation for Preventing Symptomatic Postthyroidectomy Hypocalcemia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Thyroid Neoplasm
Lead sponsor: Ewha Womans University Mokdong Hospital
Sponsor class: OTHER
First posted: 2018-03-30
Enrollment: 138
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The present study investigated the effect of routine calcium and vitamin D supplementation and tried to find the predictors for postoperative hypocalcemia in patients with thyroid cancer.

Detailed description: The present study investigated the effect of routine calcium and vitamin D supplementation and tried to find the predictors for postoperative hypocalcemia in patients with thyroid cancer. Demographic data, including age, sex, pathologic features, and postoperative laboratory test results were analyzed, as was the development of symptomatic hypocalcemia, defined as an ionized calcium concentration below 4.6 mg/dL (normal range, 4.6-5.4 mg/dL) associated with hypocalcemic symptoms. Hypocalcemia was considered permanent in patients who required calcium supplementation for longer than 6 months after thyroidectomy.

Serum concentrations of PTH and ionized calcium were measured 1 and 14 days postoperatively. Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium and 1,000 IU/day cholecalciferol for 2 weeks, beginning on the first postoperative day (POD) to the 14th POD, whereas patients in the control group received no supplementation. If symptomatic hypocalcemia developed, patients in both groups received 2.0 g of intravenous calcium, followed by oral supplementation with 3,000-4,000 mg/day elemental calcium and 1,000-2,000 IU/day cholecalciferol up to the 14th POD. If hypocalcemic symptoms were persistent or worsening 2 hours after calcium administration, patients were administered another intravenous calcium supplementation.

Eligibility criteria: Inclusion Criteria:

* patients with thyroid cancer
* euthyroid state
* underwent total thyroidectomy

Exclusion Criteria:

* previous history of neck surgery or irradiation
* calcium supplement before enrollment
* hyperthyroidism or hypothyroidism
* pregnancy

Primary outcomes:
measure: symptomatic hypocalcemia
timeFrame: postoperative day 1
measure: permanent hypocalcemia
timeFrame: postoperative 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Ewha Womans University Medical Center
Study officials:
affiliation: Ewah Womans University Medical Center
name: Hyungju Kwon, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03415516: Clinical Comparison of Universal Adhesives in Terms of Different Application Modes on the Restoration of NCCLs
Official title: Clinical Comparison of Universal Adhesives in Terms of Different Application Modes on the Restoration of NCCLs
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tooth Wear
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2018-01-30
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this randomized, controlled, prospective clinical trial is to evaluate the performances of two different universal adhesives and an etch\&rinse adhesive in restoration of non-caries cervical lesions. Twenty patients will receive restorations. Lesions will be divided into 7 groups according to adhesive systems and application modes: GSE: Gluma Universal- self etch, GSL: Gluma Universal-selective etching, GER: Gluma Universal-etch\&rinse, ASE: All Bond Universal- self etch, ASL: All Bond Universal- selective etching, AER: All Bond Universal- etch\&rinse, SB (Control): Single Bond2+etch\&rinse. Restorations (nano-hybrid composite) will be scored with regard to retention, marginal discoloration, marginal adaptation, recurrent caries and post operative sensitivity using modified USPHS criteria after 48 months. Two examiners who is not involved in the placement of restorations will conduct the evaluations. Descriptive statistics will be performed using Chi-square tests.


Eligibility criteria: Inclusion Criteria:

Inclusion criteria will be as follows:

1. being 18 years or older,
2. having no medical or behavioral problems preventing then from attending review visits,
3. having at least 7 tooth with NCCLs (d) having antagonist teeth.

Exclusion Criteria:

Exlusion criteria will be:

1. poor gingival health,
2. uncontrolled, rampant caries,
3. bruxism,
4. removable partial dentures,
5. xerostomia.

Primary outcomes:
measure: Clinical performances of different adhesives
timeFrame: Two years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01297816: Evaluation of Neuroprotective Effect of Minocycline
Official title: Evaluation of Minocycline Neuro Protective Role in Retinal Detachment Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Retinal Detachment
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2011-02-17
Sex: ALL
Minimum age (years): 8
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This process appears as a incredible and progressive event that will not stop till reattachment of RPE and neurosensory retina happened .

Process of degeneration begins from first hours of RD (Retinal Detachment) establishment Neuroprotection of photoreceptor following RD is a novel and debatable discussion encountered in recent years .

How to stop this phenomena and neuroprotective agent role in this issue are a new interest of researcher.

In the study the investigators are planning to perform a clinical trial to demonstrate the minocycline neuroprotective effect in a double blind design as this impact has been implicated previously in a animal study


Eligibility criteria: Inclusion Criteria:

* age over 8 years old
* gender of both sex
* normal liver and renal function
* informed consent received from all patients
* no pregnancy and no lactation
* minimal sun exposure

Exclusion Criteria:

* old RD
* diabetic retina
* previous retinal surgery CRF\& liver disfunction RD + PVR \> B Hyper sensitivity to tetracycline History previous MPC or PRP Patients unsuccessful SB (retina is off )

Primary outcomes:
measure: BCVA
timeFrame: changes of BCVA in 3 month
Secondary outcomes:
measure: finding of ERG changes
timeFrame: 3 months
measure: finding of OCT changes
timeFrame: 3 months
measure: finding of FAF changes
timeFrame: 3 months
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Labbafinejad medical center
Study officials:
References:
Clinical trial NCT06655116: Diabetic Foot Education
Official title: The Effect of Patient Education on Foot Care Behaviour and Diabetic Foot Self-Efficacy in Individuals With Type II Diabetes: A Randomised Controlled Study
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Diabetes Mellitus
Diabetic Foot Disease
Keywords: Diabetic Foot
Diabetes Mellitus
Patient Education
Lead sponsor: TC Erciyes University
Sponsor class: OTHER
First posted: 2024-10-23
Enrollment: 82
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Erciyes University Health Application and Research Centre

Brief summary: To determine the effect of foot care training given according to Interpersonal Relationship Theory on foot care behaviour and diabetic foot self-efficacy.


Eligibility criteria: Inclusion Criteria:

* Over 18 years of age,
* Diagnosis of Type 2 DM for at least 6 months,
* Not having received planned diabetic foot training before,
* Volunteering to participate in the study,

Exclusion Criteria:

* Neuropsychiatric drug use and disease that may affect education (Dementia- Alzheimer's and Mental Retardation etc.)
* Being visually impaired,
* Hearing impairment,
* Inability to speak Turkish,
* Presence of active diabetic foot ulcer.

Primary outcomes:
measure: Descriptive Information Form:
timeFrame: 2 Minutes
measure: Diabetic Foot Self-Care Behaviour Scale
timeFrame: 5 minutes
measure: Diabetic Foot Care Self-Efficacy Scale
timeFrame: 5 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Kayseri
country: Turkey
facility: Erciyes University
state: Talas
Study officials:
References:
Clinical trial NCT03957616: Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis
Official title: Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis in France Between 2016 and 2018
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Paraneoplastic Neurological Syndrome
Autoimmune Encephalitis
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2019-05-21
Enrollment: 600
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with a paraneoplastic neurological syndrome or autoimmune encephalitis in France and referred to the national center in Lyon between 2016 and 2018.

Brief summary: This study aims to provide an estimate of the incidence of paraneoplastic neurological syndromes and autoimmune encephalitides in France between the years 2016 and 2018. The study will describe the incidence of antibody subtypes and regional variations.


Eligibility criteria: Inclusion Criteria:

- Clinical diagnosis of Paraneoplastic Neurological Syndrome (PNS) or Autoimmune Encephalitis (AE) made by the referring physician to the national center for PNS and AE in Lyon between 2016 and 2018

Exclusion Criteria:

* Data on location of diagnosis missing
* Patients diagnosed out of the mainland French territory
* Patients for whom insufficient data was available

Primary outcomes:
measure: Incidence and prevalence of diagnosed Paraneoplastic Neurological Syndromes (PNS) and Autoimmune Encephalitis (AE) between 2016 and 2018.
timeFrame: 3 years
Secondary outcomes:
measure: Location (city) of diagnosis
timeFrame: 1 hour
measure: French general population of each counties
timeFrame: 3 years
Other outcomes:
Locations:
city: Lyon
country: France
facility: Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes
Study officials:
affiliation: center for paraneoplastic neurological syndromes and autoimmune encephalitis
name: Jérôme Honnorat
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01997216: Multifocal Lens Design Evaluation
Official title: Multifocal Lens Design Evaluation (US)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Refractive Error
Presbyopia
Keywords: contact lenses
multifocal
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2013-11-28
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: The purpose of this study was to compare binocular high contrast, high illumination (HC/HI) visual acuity at near (40 centimeters) of new multifocal contact lenses against AIR OPTIX® AQUA MULTIFOCAL contact lenses when worn for 9 hours.

Detailed description: Each participant was randomized to a specific sequence of lens wear, during which each lens type was worn bilaterally for 9 hours to compare performance characteristics.

Eligibility criteria: Inclusion Criteria:

* Sign written Informed Consent document.
* Have spectacles that provide acceptable vision and be willing to wear them if unable to wear the study lenses.
* Be presbyopic with a spectacle add ≥ 0.50 diopter.
* Currently wearing soft contact lenses at least 5 days a week.
* Other protocol-specified inclusion criteria may apply

Exclusion Criteria:

* Eye injury or surgery within 12 weeks of enrollment in this trial.
* Pre-existing ocular irritation that would preclude contact lens fitting.
* Currently enrolled in any clinical trial.
* Evidence of systemic or ocular abnormality, infection, or disease which is likely to affect successful wear of contact lenses (for at least 9 hours) or use of their accessory solutions as determined by the Investigator.
* Any use of medications for which contact lens wear could be contraindicated as determined by the Investigator.
* Binocular visual acuity worse than 20/25.
* Corrected by monovision.
* Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Mean Binocular HC/HI Visual Acuity at Near (40 cm)
timeFrame: Up to Hour 9
Secondary outcomes:
measure: Mean Binocular HC/HI Visual Acuity at Distance
timeFrame: Up to Hour 9
measure: Mean Monocular Over-refraction (OR) at Distance
timeFrame: Up to Hour 9
Other outcomes:
Locations:
Study officials:
affiliation: Alcon Research
name: Joachim Nick, Dipl.-Ing
role: STUDY_DIRECTOR
References: